

# William R Roush

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2291649/publications.pdf>

Version: 2024-02-01

64  
papers

3,493  
citations

159585

30  
h-index

144013

57  
g-index

68  
all docs

68  
docs citations

68  
times ranked

5081  
citing authors

#	ARTICLE	IF	CITATIONS
1	Sculpting a Uniquely Reactive Cysteine Residue for Site-Specific Antibody Conjugation. <i>Bioconjugate Chemistry</i> , 2022, 33, 1192-1200.	3.6	3
2	Druggable Hot Spots in the Schistosomiasis Cathepsin B1 Target Identified by Functional and Binding Mode Analysis of Potent Vinyl Sulfone Inhibitors. <i>ACS Infectious Diseases</i> , 2021, 7, 1077-1088.	3.8	9
3	Host-Derived Matrix Metalloproteinase-13 Activity Promotes Multiple Myeloma-Induced Osteolysis and Reduces Overall Survival. <i>Cancer Research</i> , 2021, 81, 2415-2428.	0.9	13
4	An Engineered Arginine Residue of Unusual pH-Sensitive Reactivity Facilitates Site-Selective Antibody Conjugation. <i>Biochemistry</i> , 2021, 60, 1080-1087.	2.5	5
5	Targeting Casein Kinase 1 Delta Sensitizes Pancreatic and Bladder Cancer Cells to Gemcitabine Treatment by Upregulating Deoxycytidine Kinase. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 1623-1635.	4.1	9
6	The dual PI3K/CK1 inhibitor umbralisib exhibits unique immunomodulatory effects on CLL T cells. <i>Blood Advances</i> , 2020, 4, 3072-3084.	5.2	52
7	Site-Selective Antibody Functionalization via Orthogonally Reactive Arginine and Lysine Residues. <i>Cell Chemical Biology</i> , 2019, 26, 1229-1239.e9.	5.2	25
8	Therapeutic Targeting of CDK12/CDK13 in Triple-Negative Breast Cancer. <i>Cancer Cell</i> , 2019, 36, 545-558.e7.	16.8	176
9	Dual-mechanistic antibody-drug conjugate via site-specific selenocysteine/cysteine conjugation. <i>Antibody Therapeutics</i> , 2019, 2, 71-78.	1.9	35
10	Restricting Glycolysis Preserves T Cell Effector Functions and Augments Checkpoint Therapy. <i>Cell Reports</i> , 2019, 29, 135-150.e9.	6.4	189
11	Discovery and Optimization of a Series of Sulfonamide Inverse Agonists for the Retinoic Acid Receptor-Related Orphan Receptor-1 $\alpha$ . <i>Medicinal Chemistry</i> , 2019, 15, 676-684.	1.5	2
12	Development of dual casein kinase 1 $\delta$ /1 $\mu$ (CK1 $\delta$ /1 $\mu$ ) inhibitors for treatment of breast cancer. <i>Bioorganic and Medicinal Chemistry</i> , 2018, 26, 590-602.	3.0	23
13	Discovery of 2-arylquinazoline derivatives as a new class of ASK1 inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2018, 28, 400-404.	2.2	10
14	Systems analysis of intracellular pH vulnerabilities for cancer therapy. <i>Nature Communications</i> , 2018, 9, 2997.	12.8	277
15	Development of matrix metalloproteinase-13 inhibitors - A structure-activity/structure-property relationship study. <i>Bioorganic and Medicinal Chemistry</i> , 2018, 26, 4984-4995.	3.0	14
16	Second Generation Triple-Helical Peptide Inhibitors of Matrix Metalloproteinases. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 3814-3827.	6.4	24
17	Stolonidiol: Synthesis, Target Identification, and Mechanism for Choline Acetyltransferase Activation. <i>Journal of the American Chemical Society</i> , 2017, 139, 5865-5869.	13.7	15
18	Enantio- and Diastereoselective Synthesis of 1,5-syn-(Z)-Amino Alcohols via Imine Double Allylboration: Synthesis of trans-1,2,3,6-Tetrahydropyridines and Total Synthesis of Andrachcine. <i>Organic Letters</i> , 2017, 19, 2646-2649.	4.6	17

#	ARTICLE	IF	CITATIONS
19	Harnessing a catalytic lysine residue for the one-step preparation of homogeneous antibody-drug conjugates. <i>Nature Communications</i> , 2017, 8, 1112.	12.8	71
20	Novel Pharmacological Probes Reveal ABHD5 as a Locus of Lipolysis Control in White and Brown Adipocytes. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2017, 363, 367-376.	2.5	23
21	<i>In Silico</i> HTS and Structure Based Optimization of Indazole-Derived ULK1 Inhibitors. <i>ACS Medicinal Chemistry Letters</i> , 2017, 8, 1258-1263.	2.8	22
22	Structure-Based Design and Synthesis of Potent and Selective Matrix Metalloproteinase 13 Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 5816-5825.	6.4	35
23	Functional Roles of Acetylated Histone Marks at Mouse Meiotic Recombination Hot Spots. <i>Molecular and Cellular Biology</i> , 2017, 37, .	2.3	35
24	4-aminopyridyl-based lead compounds targeting CYP51 prevent spontaneous parasite relapse in a chronic model and improve cardiac pathology in an acute model of <i>Trypanosoma cruzi</i> infection. <i>PLoS Neglected Tropical Diseases</i> , 2017, 11, e0006132.	3.0	24
25	Human Serum Albumin Domain I Fusion Protein for Antibody Conjugation. <i>Bioconjugate Chemistry</i> , 2016, 27, 2271-2275.	3.6	15
26	Fluorometric High-Throughput Screening Assay for Secreted Phospholipases A2 Using Phospholipid Vesicles. <i>Journal of Biomolecular Screening</i> , 2016, 21, 713-721.	2.6	3
27	Synthesis and Evaluation of Oxyguanidine Analogues of the Cysteine Protease Inhibitor WRR-483 against Cruzain. <i>ACS Medicinal Chemistry Letters</i> , 2016, 7, 77-82.	2.8	26
28	Exploiting the co-reliance of tumours upon transport of amino acids and lactate: Gln and Tyr conjugates of MCT1 inhibitors. <i>MedChemComm</i> , 2016, 7, 900-905.	3.4	4
29	A CK1 $\mu$ /CK1 $\beta$ -to-Wnt $\beta$ -Catenin Circuit Is a Therapeutic Vulnerability in Primary and Drug Resistant Multiple Myeloma. <i>Blood</i> , 2016, 128, 2094-2094.	1.4	0
30	Identification of Target Pathways Induced By the Multiple Myeloma Tumor Microenvironment Using Activity-Based Protein Profiling and Ex Vivo Protein Kinase Inhibitor Screening. <i>Blood</i> , 2016, 128, 3288-3288.	1.4	0
31	CK1 $\beta$ : an exploitable vulnerability in breast cancer. <i>Annals of Translational Medicine</i> , 2016, 4, 474-474.	1.7	1
32	Advancing Biological Understanding and Therapeutics Discovery with Small-Molecule Probes. <i>Cell</i> , 2015, 161, 1252-1265.	28.9	135
33	Identification of Histone Deacetylase Inhibitors with Benzoylhydrazide Scaffold that Selectively Inhibit Class I Histone Deacetylases. <i>Chemistry and Biology</i> , 2015, 22, 273-284.	6.0	80
34	Therapeutic targeting of casein kinase 1 $\beta$ in breast cancer. <i>Science Translational Medicine</i> , 2015, 7, 318ra202.	12.4	61
35	Antiproliferation Activity of a Small Molecule Repressor of Liver Receptor Homolog 1. <i>Molecular Pharmacology</i> , 2015, 87, 296-304.	2.3	42
36	Hrr25/CK1 $\beta$ -directed release of Ltv1 from pre-40S ribosomes is necessary for ribosome assembly and cell growth. <i>Journal of Cell Biology</i> , 2015, 208, 745-759.	5.2	71

#	ARTICLE	IF	CITATIONS
37	Casein Kinase 1 $\delta$ Is an APC/CCdh1 Substrate that Regulates Cerebellar Granule Cell Neurogenesis. <i>Cell Reports</i> , 2015, 11, 249-260.	6.4	30
38	Targeting Ergosterol Biosynthesis in <i>Leishmania donovani</i> : Essentiality of Sterol 14 $\alpha$ -demethylase. <i>PLoS Neglected Tropical Diseases</i> , 2015, 9, e0003588.	3.0	90
39	Endogenous and Synthetic ABHD5 Ligands Regulate ABHD5-Perilipin Interactions and Lipolysis in Fat and Muscle. <i>Cell Metabolism</i> , 2015, 22, 851-860.	16.2	87
40	Casein Kinase 1 $\delta$ -dependent Wee1 Protein Degradation. <i>Journal of Biological Chemistry</i> , 2014, 289, 18893-18903.	3.4	22
41	Characterization of Selective Exosite-Binding Inhibitors of Matrix Metalloproteinase 13 That Prevent Articular Cartilage Degradation in Vitro. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 9598-9611.	6.4	29
42	Binding Mode and Potency of <i>N</i> -Indolylloxopyridinyl-4-aminopropanyl-Based Inhibitors Targeting <i>Trypanosoma cruzi</i> CYP51. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 10162-10175.	6.4	22
43	<i>R</i> -Configuration of 4-Aminopyridyl-Based Inhibitors of CYP51 Confers Superior Efficacy Against <i>Trypanosoma cruzi</i> . <i>ACS Medicinal Chemistry Letters</i> , 2014, 5, 434-439.	2.8	18
44	Expanding the Binding Envelope of CYP51 Inhibitors Targeting <i>Trypanosoma cruzi</i> with 4-Aminopyridyl-Based Sulfonamide Derivatives. <i>ChemBioChem</i> , 2014, 15, 1111-1120.	2.6	18
45	Drug Strategies Targeting CYP51 in Neglected Tropical Diseases. <i>Chemical Reviews</i> , 2014, 114, 11242-11271.	47.7	74
46	4-Aminopyridyl-Based CYP51 Inhibitors as Anti- <i>Trypanosoma cruzi</i> Drug Leads with Improved Pharmacokinetic Profile and in Vivo Potency. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 6989-7005.	6.4	43
47	Rational Development of 4-Aminopyridyl-Based Inhibitors Targeting <i>Trypanosoma cruzi</i> CYP51 as Anti-Chagas Agents. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 7651-7668.	6.4	43
48	Enantio- and Diastereoselective Synthesis of <i>N</i> -Acetyl Dihydrotetrafrabricin Methyl Ester. <i>Journal of the American Chemical Society</i> , 2013, 135, 5340-5343.	13.7	20
49	Development of highly selective casein kinase 1 $\delta$ /1 $\mu$ (CK1 $\delta$ /1 $\mu$ ) inhibitors with potent antiproliferative properties. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 4374-4380.	2.2	65
50	Enantioselective Synthesis of ( <i>Z</i> )- and ( <i>E</i> )-2-Methyl-1,5-anti-Pentenediols via an Allene Hydroboration-Double-Allylboration Reaction Sequence. <i>Journal of the American Chemical Society</i> , 2013, 135, 9512-9517.	13.7	55
51	Enantio- and Diastereoselective Synthesis of ( <i>E</i> )-1,5-syn-Diols: Application to the Synthesis of the C(23)-C(40) Fragment of Tetrafrabricin. <i>Organic Letters</i> , 2011, 13, 1868-1871.	4.6	37
52	Identification of novel, exosite-binding matrix metalloproteinase-13 inhibitor scaffolds. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 7180-7184.	2.2	30
53	Development of a double allylboration reagent targeting 1,5-syn-( <i>E</i> )-diols: application to the synthesis of the C(23)-C(40) fragment of tetrafrabricin. <i>Tetrahedron</i> , 2011, 67, 6497-6512.	1.9	25
54	Stereoselective Synthesis of $\beta$ -Substituted ( <i>Z</i> )-Allylic Boranes via Kinetically Controlled Hydroboration of Allenes with 10-TMS-9-borabicyclo[3.3.2]decane. <i>Journal of the American Chemical Society</i> , 2009, 131, 14174-14175.	13.7	87

#	ARTICLE	IF	CITATIONS
55	Stereoselective Synthesis of the C(1)~C(11) Fragment of Peloruside A. <i>Organic Letters</i> , 2005, 7, 3941-3944.	4.6	59
56	Synthesis of the C(1)~C(25) Fragment of Amphidinol 3:~ Application of the Double-Allylboration Reaction for Synthesis of 1,5-Diols. <i>Organic Letters</i> , 2005, 7, 1411-1414.	4.6	71
57	Synthesis of the C(43)~C(67) Fragment of Amphidinol 3. <i>Organic Letters</i> , 2005, 7, 5509-5512.	4.6	55
58	Relative Rates of Michael Reactions of ~-(Phenethyl)thiol with Vinyl Sulfones, Vinyl Sulfonate Esters, and Vinyl Sulfonamides Relevant to Vinyl Sulfonyl Cysteine Protease Inhibitors. <i>Organic Letters</i> , 2003, 5, 1967-1970.	4.6	103
59	Structure-Activity Relationships for Inhibition of Cysteine Protease Activity and Development of Plasmodium falciparum by Peptidyl Vinyl Sulfones. <i>Antimicrobial Agents and Chemotherapy</i> , 2003, 47, 154-160.	3.2	157
60	Enantioselective Synthesis of 1,5-anti- and 1,5-syn-Diols Using a Highly Diastereoselective One-Pot Double Allylboration Reaction Sequence. <i>Journal of the American Chemical Society</i> , 2002, 124, 13644-13645.	13.7	166
61	Potent second generation vinyl sulfonamide inhibitors of the trypanosomal cysteine protease cruzain. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2001, 11, 2759-2762.	2.2	82
62	Active site mapping, biochemical properties and subcellular localization of rhodesain, the major cysteine protease of Trypanosoma brucei rhodesiense. <i>Molecular and Biochemical Parasitology</i> , 2001, 118, 61-73.	1.1	155
63	A target within the target: probing cruzain's P1~ site to define structural determinants for the Chagas~ disease protease. <i>Structure</i> , 2000, 8, 831-840.	3.3	100
64	Vinyl Sulfonate Esters and Vinyl Sulfonamides:~ Potent, Irreversible Inhibitors of Cysteine Proteases. <i>Journal of the American Chemical Society</i> , 1998, 120, 10994-10995.	13.7	196